Efficacy and Safety of Imatinib Mesylate Plus Hydroxyurea (HU) in Patients With Recurrent Glioblastoma Multiforme (GBM)
Status:
Terminated
Trial end date:
2008-08-01
Target enrollment:
Participant gender:
Summary
This was an investigational study to assess the objective overall response (OOR) rate
(complete response [CR] + partial response [PR]) of imatinib mesylate and hydroxyurea
(hydroxycarbamide) combination therapy in patients with recurrent glioblastoma multiforme
(brain tumors). This study also evaluated the duration of tumor response (as per MacDonald
criteria), clinical benefit, progression-free survival rate at 6 and 12 months, and the
survival rate at 12 and 24 months.